Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 59

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Small molecule compounds targeting the p53 pathway: are we finally making progress?

Yu, Xin, Narayanan, Sumana, Vazquez, Alexei, Carpizo, Darren R.·2014·Apoptosis
DOI 10.1007/s10495-014-0990-3
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10495-014-0990-3

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Research works printed but not linked: 77

  1. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493–502 · DOI · Paper page
  2. Joensuu H (2012) Adjuvant treatment of GIST: patient selection and treatment strategies. Nat Rev Clin Oncol 9:351–358 · DOI
  3. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139 · DOI · Paper page
  4. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323–331 · DOI · Paper page
  5. Vousden KH, Lu X (2002) Live or let die: the cell’s response to p53. Nat Rev Cancer 2:594–604 · DOI · Paper page
  6. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275:8945–8951 · DOI · Paper page
  7. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299 · DOI · Paper page
  8. Midgley CA, Lane DP (1997) p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15:1179–1189 · DOI · Paper page
  9. Li D, Marchenko ND, Schulz R et al (2011) Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Molecular cancer research : MCR 9:577–588 · DOI · Paper page
  10. Sigal A, Rotter V (2000) Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60:6788–6793
  11. Adorno M, Cordenonsi M, Montagner M et al (2009) A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137:87–98 · DOI · Paper page
  12. Dittmer D, Pati S, Zambetti G et al (1993) Gain of function mutations in p53. Nat Genet 4:42–46 · DOI · Paper page
  13. Liu G, McDonnell TJ, de Oca Montes, Luna R et al (2000) High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA 97:4174–4179 · DOI · Paper page
  14. Sherr CJ, Weber JD (2000) The ARF/p53 pathway. Curr Opin Genet Dev 10:94–99 · DOI · Paper page
  15. Lane DP, Cheok CF, Lain S (2010) p53-based cancer therapy. Cold Spring Harb Perspect Biol 2:a001222
  16. Bouchet BP, Caron de Fromentel C, Puisieux A, Galmarini CM (2006) p53 as a target for anti-cancer drug development. Crit Rev Oncol/Hematol 58:190–207 · DOI
  17. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR (2008) Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 105:10360–10365 · DOI · Paper page
  18. Joerger AC, Ang HC, Fersht AR (2006) Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci USA 103:15056–15061 · DOI · Paper page
  19. Wassman CD, Baronio R, Demir O et al (2013) Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat Commun 4:1407 · DOI · Paper page
  20. Freed-Pastor WA, Prives C (2012) Mutant p53: one name, many proteins. Genes Dev 26:1268–1286 · DOI · Paper page
  21. Wang W, Kim SH, El-Deiry WS (2006) Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci USA 103:11003–11008 · DOI
  22. Kravchenko JE, Ilyinskaya GV, Komarov PG et al (2008) Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 105:6302–6307 · DOI · Paper page
  23. Yu X, Vazquez A, Levine AJ, Carpizo DR (2012) Allele-specific p53 mutant reactivation. Cancer Cell 21:614–625 · DOI · Paper page
  24. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813–823 · DOI · Paper page
  25. Ikediobi ON, Davies H, Bignell G et al (2006) Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5:2606–2612 · DOI · Paper page
  26. Peltonen K, Colis L, Liu H et al (2010) Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS One 5:e12996 · DOI
  27. Chene P (2004) Inhibition of the p53-MDM2 interaction: targeting a protein–protein interface. Mol Cancer Res 2:20–28 · DOI
  28. Chen L, Agrawal S, Zhou W, Zhang R, Chen J (1998) Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA 95:195–200 · DOI · Paper page
  29. Wasylyk C, Salvi R, Argentini M et al (1999) p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 18:1921–1934 · DOI
  30. Tortora G, Caputo R, Damiano V et al (2000) A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Int J Cancer 88:804–809 · DOI
  31. Vassilev LT (2007) MDM2 inhibitors for cancer therapy. Trends Mol Med 13:23–31 · DOI · Paper page
  32. Vassilev LT, Vu BT, Graves B et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844–848 · DOI · Paper page
  33. Tovar C, Graves B, Packman K et al (2013) MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res 73:2587–2597 · DOI · Paper page
  34. Saha MN, Qiu L, Chang H (2013) Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol 6:23 · DOI
  35. Brown CJ, Cheok CF, Verma CS, Lane DP (2011) Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci 32:53–62 · DOI
  36. Zou P, Zheng N, Yu Y et al (2012) Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics. J Pharm Pharm Sci 15:265–280 · DOI
  37. Issaeva N, Bozko P, Enge M et al (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10:1321–1328 · DOI · Paper page
  38. Krajewski M, Ozdowy P, D’Silva L, Rothweiler U, Holak TA (2005) NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med 11:1135–1136 author reply 1136–1137 · DOI
  39. Saha MN, Jiang H, Yang Y et al (2012) Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. PLoS One 7:e30215 · DOI
  40. Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G (2010) Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle 9:1847–1855 · DOI · Paper page
  41. Roh JL, Ko JH, Moon SJ, Ryu CH, Choi JY, Koch WM (2012) The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. Cancer Lett 325:35–41 · DOI
  42. Wang X, Wang J, Jiang X (2011) MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J Biol Chem 286:23725–23734 · DOI
  43. Huang L, Yan Z, Liao X et al (2011) The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci USA 108:12001–12006 · DOI · Paper page
  44. Vassilev LT (2005) p53 Activation by small molecules: application in oncology. J Med Chem 48:4491–4499 · DOI · Paper page
  45. Hu B, Gilkes DM, Chen J (2007) Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 67:8810–8817 · DOI · Paper page
  46. Graves B, Thompson T, Xia M et al (2012) Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci USA 109:11788–11793 · DOI · Paper page
  47. Wang H, Yan C (2011) A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. Neoplasia 13:611–619 · DOI
  48. Lain S, Hollick JJ, Campbell J et al (2008) Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13:454–463 · DOI · Paper page
  49. Gudkov AV, Komarova EA (2003) The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 3:117–129 · DOI · Paper page
  50. Mendrysa SM, McElwee MK, Michalowski J, O’Leary KA, Young KM, Perry ME (2003) mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23:462–472 · DOI · Paper page
  51. Canner JA, Sobo M, Ball S et al (2009) MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br J Cancer 101:774–781 · DOI
  52. Graat HC, Carette JE, Schagen FH et al (2007) Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. Mol Cancer Ther 6:1552–1561 · DOI
  53. Cheok CF, Dey A, Lane DP (2007) Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Mol Cancer Res 5:1133–1145 · DOI
  54. Levine AJ, Wu MC, Chang A et al (1995) The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a “gain of function” phenotype. Ann N Y Acad Sci 768:111–128 · DOI
  55. Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286:2507–2510 · DOI · Paper page
  56. Haupt S, Haupt Y (2004) Manipulation of the tumor suppressor p53 for potentiating cancer therapy. Semin Cancer Biol 14:244–252 · DOI
  57. Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR (2002) Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21:2119–2129 · DOI · Paper page
  58. Bykov VJ, Issaeva N, Zache N et al (2005) Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 280:30384–30391 · DOI · Paper page
  59. Wiman KG (2010) Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 29:4245–4252 · DOI · Paper page
  60. Liu X, Wilcken R, Joerger AC et al (2013) Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res 41:6034–6044 · DOI · Paper page
  61. Puca R, Nardinocchi L, Porru M et al (2011) Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 10:1679–1689 · DOI
  62. Yu Y, Kalinowski DS, Kovacevic Z et al (2009) Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem 52:5271–5294 · DOI · Paper page
  63. Terzian T, Suh YA, Iwakuma T et al (2008) The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22:1337–1344 · DOI · Paper page
  64. DeBerardinis RJ, Mancuso A, Daikhin E et al (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104:19345–19350 · DOI · Paper page
  65. Michalak EM, Villunger A, Adams JM, Strasser A (2008) In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ 15:1019–1029 · DOI · Paper page
  66. Li T, Kon N, Jiang L et al (2012) Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149:1269–1283 · DOI · Paper page
  67. Blagosklonny MV (2012) Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression? Aging (Albany NY) 4:450–455 · DOI
  68. Feng Z, Hu W, de Stanchina E et al (2007) The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 67:3043–3053 · DOI · Paper page
  69. Feng Z, Zhang H, Levine AJ, Jin S (2005) The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 102:8204–8209 · DOI · Paper page
  70. Janes MR, Fruman DA (2010) Targeting TOR dependence in cancer. Oncotarget 1:69–76 · DOI
  71. Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH (2013) Metabolic regulation by p53 family members. Cell Metab 18:617–633 · DOI · Paper page
  72. Cheung EC, Athineos D, Lee P et al (2013) TIGAR is required for efficient intestinal regeneration and tumorigenesis. Dev Cell 25:463–477 · DOI
  73. Gottlieb E, Vousden KH (2010) p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol 2:a001040 · DOI · Paper page
  74. Buzzai M, Jones RG, Amaravadi RK et al (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745–6752 · DOI · Paper page
  75. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z (2010) Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA 107:7455–7460 · DOI · Paper page
  76. Desilet N, Campbell TN, Choy FY (2010) p53-based anti-cancer therapies: an empty promise? Curr Issues Mol Biol 12:143–146
  77. Brooks CL, Gu W (2008) p53 Activation: a case against Sir. Cancer Cell 13:377–378 · DOI

Cited by

See all 59

Metadata

Authors
Yu, X., Narayanan, S., Vazquez, A., & Carpizo, D. R.
Venue
Apoptosis
Publisher
Springer Science and Business Media LLC
Published
2014-04-23
Volume
19
Issue
7
Pages
1055-1068
ISSN
  • 1360-8185
  • 1573-675X
DOI
10.1007/s10495-014-0990-3
Cited by
59
References
40
Language
en
Licence
creativecommons.org/licenses/by/4.0 (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Small molecule compounds targeting the p53 pathway: are we finally making progress? https://app.cochat.ai/papers/10.1007/s10495-014-0990-3
The paper
Yu, X., Narayanan, S., Vazquez, A., & Carpizo, D. R. (2014). Small molecule compounds targeting the p53 pathway: are we finally making progress? Apoptosis. https://doi.org/10.1007/s10495-014-0990-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.